Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Groot, S. de
  • (-) ≠ Baak-Pablo, R.
  • (-) ≠ IGF-BP3
  • (-) = Liefers, G.J.

Search results

  • RSS Feed
(1 - 3 of 3)
Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
Groot, S. de; Pijl, H.; Charehbili, A.; Ven, S. van de; Smit, V.T.H.B.M.; Meershoek-Klein Kranenbarg, E.; ... ; Dutch Breast Canc Res Grp 2019
Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
Article / Letter to editor
metadata only
Thyroid function is associated with the response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial on behalf of the Dutch Breast Cancer Research Group (BOOG 2010-01)
Groot, S. de; Charehbili, A.; Janssen, L.G.M.; Dijkgraaf, E.M.; Smit, V.T.H.B.M.; Kessels, L.W.; ... ; Kroep, J.R. 2015
Thyroid function is associated with the response to neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial on behalf of the Dutch Breast Cancer Research Group (BOOG 2010-01)
Article / Letter to editor
metadata only
DIRECT: A phase II/III randomized trial with dietary restriction as an adjunct to neoadjuvant chemotherapy for HER2-negative breast cancer
Groot, S. de; Vreeswijk, M.P.G.; Smit, V.T.H.B.M.; Heijns, J.B.; Imholz, A.L.T.; Kessels, L.W.; ... ; Kroep, J.R. 2013
DIRECT: A phase II/III randomized trial with dietary restriction as an adjunct to neoadjuvant chemotherapy for HER2-negative breast cancer
Article / Letter to editor
metadata only